REPL: 26% | Replimune Group shares are trading higher after the company announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.
GAP: 16% | Gap shares are trading higher after the company reported better-than-expected Q3 EPS and sales.
KSCP: -38% | Knightscope shares are trading lower after the company announced a proposed public offering of Class A common stock and pre-funded warrants to address working capital needs.
